To evaluate portal-enteric (PE) pancreas and kidney transplantation with venting jejunostomy (VJ) for its efficacy, safety, and reproducibility.
Objective
To evaluate portal-enteric (PE) pancreas and kidney transplantation with venting jejunostomy (VJ) for its efficacy, safety, and reproducibility.
Summary Background Data
Simultaneous pancreas and kidney transplantation for patients with long-standing insulin-dependent diabetes mellitus that progresses to renal failure has revolutionized their treatment and quality of life. A current clinical focus is to refine the technical aspects of this procedure. Simultaneous pancreas and kidney transplantation with PE anastomosis with VJ appears to offer several advantages over bladder drainage. VJ allows initial decompression of the enteric anastomosis, monitoring of pancreatic function by ostomy amylase, and simple access for endoscopic evaluation and biopsy of the allograft.
Methods
Simultaneous pancreas and kidney transplantation with VJ was performed in 21 patients from December 1996 to October 2000 at Willis Knighton/LSU Regional Transplant Center. All patients had long-standing insulin-dependent diabetes mellitus and subsequent renal failure. They were evaluated at the time of surgery by a multidisciplinary transplant team and monitored for numerous factors, including length of hospital stay, immunosuppressive regimen, and ischemia times. All patients had intermittent visual and biochemical evaluation of pancreatic secretions monitored by means of the VJ.
Results
Of the 21 patients, 10 were women and 11 were men. Four patients were black and 17 were white. The mean age at transplantation was 38 years; average human leukocyte antigen (HLA) match was one; and average cold ischemia time was 12 hours. The median hospital stay was 16 days. Four episodes of postoperative bleeding requiring exploration occurred in four patients. Postoperative wound infections developed in four patients. There were 12 episodes of rejection in nine patients. All patients with suspected acute pancreatic rejection underwent endoscopy by means of the VJ and duodenal biopsy for evaluation. Two patients lost pancreatic function subsequent to kidney failure, one secondary to noncompliance and the other as a result of hemolytic-uremic syndrome. Patient, kidney, and pancreatic survival rates were 100%, 90%, and 90%, respectively. The mean follow-up period was 25 (range 2-48) months.
Conclusion
The authors believe that PE pancreatic drainage with VJ is a more physiologic method to perform pancreatic transplantation than bladder drainage. PE drainage allows rapid diagnosis of acute rejection and anastomotic leak and provides a simple way to monitor ostomy amylase and transplant duodenal bleeding. This technique is safe and has minimal associated complications.
Transplantation of the pancreas is a treatment modality for insulin-dependent diabetes mellitus that reliably results in an insulin-free state with euglycemia and normal glycosylated hemoglobin levels. 1, 2 Various techniques have been used during the past three decades to manage pancreatic exocrine secretions after whole organ pancreas transplantation, including enteric drainage, 3 ureteral drainage, 4 open peritoneal drainage, 5 and pancreatic duct occlusion. 6 Most of the nearly 14,000 pancreas transplants reported to the International Pancreas Transplant Registry and the United Network for Organ Sharing have been performed using bladder drainage of exocrine secretions ( Fig. 1 ). 7 Since 1994, the proportion of enteric-drained pancreas transplant cases has steadily increased. In 1998, enteric drainage (ED) accounted for 60% of the cases where duct management was reported. 7 In 1993, Gaber et al 8 modified the surgical technique developed for ED in pancreas transplant recipients 3 that resulted in portal venous delivery of insulin. Patients who undergo portal-enteric (PE) pancreas transplants do not have the volume depletion and metabolic acidosis experienced by patients who have bladder-systemic pancreas transplants. In addition, in patients with PE transplants, insulin is physiologically secreted into the portal circulation, in contrast to the systemic venous circulation in bladder-systemic transplants.
Unfortunately, access to urinary amylase measurement as an indication of acute rejection is lost with PE transplantation. The loss of this specific marker of pancreatic allograft rejection has been the major obstacle of long-term follow-up of such patients. 9, 10 Currently, diagnosis of acute rejection in pancreas transplantation with ED relies on percutaneous, laparoscopic, or open surgical biopsies.
Previously, we described a technique of Roux-en-Y venting jejunostomy (VJ) as an approach to monitor rejection and prevent anastomotic leak in pancreas transplants. 11 The goals of the current study were to evaluate the efficacy and safety of this technique in patients receiving simultaneous pancreas and kidney transplants.
METHODS
Simultaneous pancreas and kidney transplantation with VJ was performed in 21 patients at Willis Knighton/LSU Regional Transplant Center in Shreveport from December 1996 to October 2000. All patients had long-standing insulin-dependent diabetes mellitus and subsequent renal failure. All patients underwent transplantation with PE drainage as described by Gaber et al 8 and Roux-en-Y VJ. 11 The technique of Gaber et al 8 was modified such that instead of an end-to-end duodenojejunal anastomosis between the distal end of the donor duodenum and the defunctionalized limb of the Roux-en-Y recipient, the distal end of the donor duodenum was anastomosed to the side of the Roux-en-Y and the end of the Roux-en-Y was anastomosed to the skin to form a VJ ( Fig. 2 ). Patients were treated after surgery with either low-dose intravenous heparin or low-molecularweight dextran (LMD 40) to prevent vessel thrombosis. All patients were evaluated, followed up, and treated by a multidisciplinary transplant team. Treatment consisted of quadruple-drug therapy (OKT3, prednisone, cyclosporine, mycophenolate mofetil). Biochemical evaluations of pancreatic secretions (e.g., amylase) and serum (e.g., glucose, amylase) were performed on all patients. Endoscopic donor duodenal biopsies were performed when acute pancreatic rejection was suspected or in cases of suspected gastrointestinal bleeding.
Patients were evaluated approximately 1 year after the transplant for jejunostomy closure. Patients with stable allograft function and without recent rejection or bleeding episodes were candidates for takedown. The 1-year interval from transplant to jejunostomy closure was chosen based on the likelihood that most complications would have occurred during this period.
RESULTS
There were 11 men and 10 women included in this study. Seventeen patients were white. The mean age was 38 (range 28 -55) years. Patients had had diabetes for an average of 26 years before the transplant. The mean waiting time was 15 months. The median HLA match was one antigen. The mean cold ischemic time of organ preservation was 13 hours. Eighteen patients were anticoagulated with low-dose intravenous heparin; three patients received LMD 40. Patient, kidney, and pancreas graft survival rates were 100%, 90%, and 90%, respectively. Renal allograft failure occurred in two patients, who subsequently also had rejection of their pancreas allografts. These patients returned to insulin therapy. The cause of renal/pancreas graft failure was noncompliance with immunosuppressive therapy in one patient and hemolytic-uremic syndrome in the second patient.
Acute rejection occurred 12 times among nine patients during a mean follow-up period of 25 (range 2-48) months. Of these, six involved the kidney only, three involved only the pancreas, and three involved both the kidney and pancreas allografts. Four of the 12 rejection episodes were steroid-resistant and required antibody therapy. Patients with suspected pancreatic rejection underwent endoscopic evaluation. Among the patients with acute pancreatic rejection (i.e., displaying significant mononuclear lymphocytic infiltration at biopsy), the transplanted duodenal mucosa was friable and ulcerated ( Fig. 3 ).
Postoperative bleeding occurred in four patients. All four received intravenous heparin therapy. Vessel thrombosis did not occur in any patient. Wound infections developed in Pancreatic Transplantation and Graft Biopsy Via Jejunostomy four patients after surgery, and in one of these patients an anastomotic leak occurred 3 months after surgery. Acute tubular necrosis requiring hemodialysis occurred in two patients. Perioperative myocardial infarction did not occur in any patient. Late complications included gastrointestinal hemorrhage (n ϭ 1), perforation of donor duodenum (n ϭ 2), and acalculous cholecystitis (n ϭ 1).
Jejunostomy closure was performed in 12 of 21 patients. The mean time to closure was 12 (range 9 -16) months. One episode of postoperative bleeding occurred during closure; it required immediate reexploration for mesenteric bleeding.
DISCUSSION
As of August 2000, nearly 10,000 pancreas transplants in the United States have been reported to the International Pancreas Transplant Registry and the United Network for Organ Sharing. Most have been drained into the urinary bladder. 7, [11] [12] [13] [14] Although bladder drainage may facilitate early management because of the ability to monitor urinary amylase as a surrogate marker of acute pancreatic rejection, this technique is associated with a 5-year enteric conversion rate of 24%. The most common indications were leak (44%), urethritis (23%), hematuria (19%), and recurrent urinary tract infections (11%). 15 Additional consequences of bladder drainage include postoperative bicarbonate replacement and multiple admissions for dehydration. Thus, PE drainage as the primary technique for pancreatic transplantation has become an attractive option. Not only is the patient spared volume depletion and metabolic acidosis, but also insulin is secreted physiologically into the portal circulation. 4, 11, 16, 17 The total number of cases and centers performing ED has dramatically increased (from 29% to 94%). In fact, in 1998, in 60% of the cases reported to the International Pancreas Transplant Registry and the United Network for Organ Sharing, the method of drainage was enteric. 7 One disadvantage of ED is the inability to measure urinary amylase as a marker of acute pancreatic rejection. Thus, diagnosis of rejection is dependent on alternative clinical markers of pancreatic function, such as serum amylase. However, Klassen et al 18 reported that only 79% of patients with elevated serum amylase levels had biopsyproven rejection. Thus, elevated serum markers are not sufficient to initiate antirejection therapy, and a needle biopsy is required. However, obtaining a biopsy sample is not a trivial issue in these patients. In fact, adequate biopsy tissue from ED pancreas transplant patients was obtained only 72% of the time when performed percutaneously and 87% of the time when performed cystoscopically. 19 Thus, at least 13% of patients would not have adequate tissue to analyze. The VJ that we developed allowed us to perform endoscopic biopsies easily; these contain adequate tissue for analysis 100% of the time.
The Roux-en-Y VJ allows the endoscopist easily to diagnose and treat transplant duodenal bleeding and perforations. The incidence of gastrointestinal bleeding early and late after an ED pancreas transplant is unknown. Barone et al 20 reported a case of late gastrointestinal bleeding as a result of an ulcer in the transplant duodenum secondary to cytomegalovirus infection. Localization of the bleeding required surgical intervention because this ulcer was not amenable to endoscopy. A VJ in such a patient would have allowed an early diagnosis of cytomegalovirus infection and would have averted surgical intervention.
Acute rejection involving the transplanted kidney, pancreas, or both occurred in 43% of the patients in this study. Twenty-five percent of these rejection episodes were pancreas only, and another 25% were combined kidney/pancreas rejection. The incidence of pancreatic rejection in our patient population was higher than expected. Biopsy of the donor duodenum is easily and safely achieved by means of the VJ and allows patients with a presumptive diagnosis of mild rejection the benefit of a tissue diagnosis before the administration of steroids. This aggressive approach to donor duodenum biopsy may increase the sensitivity for detecting rejection in pancreatic transplant patients with VJ.
The ostomy is a convenient site to introduce Gastrografin for small bowel follow-through X-ray studies to rule out anastomotic and duodenal stump leaks. Pancreatic amylase and other markers of rejection can be readily measured in ostomy fluid. The Roux-en-Y VJ also allows the endoscopist to perform endoscopic retrograde cholangiopancreatography if needed to visualize the pancreatic duct, as well as to obtain a biopsy sample from the pancreas. Except for one case of bleeding, there were no other complications after closure of the ostomy 9 to 16 months after the transplant, and this procedure appears to be safe. Placement of the Roux-en-Y loop did not adversely affect the outcome of pancreatic transplants at our center.
Our results suggest that the Roux-en-Y VJ with PE transplantation can be used safely to diagnose and monitor acute pancreas rejection, and prevent and diagnose anastomotic leaks. This technique can potentially be used to obtain pancreatic secretions for analysis, to diagnose and treat transplant duodenal bleeding, and to perform endoscopic retrograde cholangiopancreatography to visualize the pancreatic duct or obtain pancreatic biopsy samples. We predict this new technique will be especially useful among recipients of solitary pancreatic transplants.
Discussion
DR. ANDREW KLEIN (Baltimore, Maryland): I rise to commend Dr. Zibari and his colleagues at LSU-Shreveport for the development and evaluation of an innovative strategy in pancreas transplantation, which combines the physiologic advantages of portal venous drainage with the ability to monitor endocrine and exocrine function via the venting jejunostomy. I have three questions I would like to ask Dr. Zibari. It has been suggested that exposure of transplant recipients to certain infectious agents, specifically certain gram-positive bacte-ria, may trigger acute allograft rejection. In your series, 20% to 25% of the patients had a wound infection and slightly less than half of the patients had acute rejection episodes. This rejection rate is somewhat higher than has been previously reported by Dr. Gaber and others with a similar technique, so do you think that the presence of the venting jejunostomy was a causative factor in the development of these wound infections? Furthermore, as a corollary, are you concerned that as a result this technique will at least indirectly lead to an increased risk of graft rejection?
My second question: Of the 25 kidney-pancreas recipients in your series, 4 were reconstructed via the systemic bladder drainage methodology and 21 underwent portal-enteric drainage. If your analysis is confined to those patients that had the portal-enteric procedure, how are the infection rates and the incidence of acute rejection affected?
Finally, recent reports have suggested that posttransplant hypertension in diabetics may be less common and less severe in those that receive a simultaneous kidney-pancreas compared to those who receive a kidney alone. Jim Schulak and the group from Case Western Reserve found that this beneficial effect was limited to those patients with the bladder-drained pancreas; it did not accrue to those that have enterically drained allografts. Have you had the opportunity to evaluate your postoperative blood pressure control in your patients that have this portal-enteric anastomosis and a venting jejunostomy?
I would like to thank Dr. Zibari for providing me with a copy of his manuscript for review, and again I congratulate him for his innovative contributions.
DR. JOSEPH COFER (Chattanooga, Tennessee): I appreciate the chance to discuss this excellent presentation from a good friend and new member, Gazi Zibari, and I also appreciate the chance to have read the manuscript prior to this.
It has been my experience that whenever a transplant surgeon is speaking to nontransplanters, it is often like a Greek speaking to a Roman. So let me tell you why I think this paper is important. The old way, simplistically put, to do a pancreas transplant was to put it in the pelvis. When you did this, you sewed the neoduodenum, the duodenum of the donor, to the bladder of the recipient. This handled the excretion of the pancreas and had a lot of complications (as Gazi has mentioned, with cystitis, bicarbonate loss, and volume loss), but had the theoretic and to some degree real advantage of being able to monitor amylase in the urine to predict rejection. The vessels, the old way, were sewn to the iliac vessels. This worked fine from a technical standpoint but had the disadvantage of submitting the insulin to the body in such a way that the liver saw it on the second pass. It went to the systemic circulation first and then to the liver second. Now the new way of doing a pancreas transplant-and this work has to a large degree been developed by Dr. Gaber of UT-Memphis, who is a fellow of this organization-has sort of taken over. He presented data showing the old way was pretty much done most of the time in 1988, but by late 1990s, over half the pancreas transplants were done the new way. Now, the new way is, you put the pancreas in the midabdomen and you sew the duodenum of the new pancreas to the intestines of the recipient. This allows for all of the problems with the digestive enzymes being put into the bladder. This is replaced by putting all of the digestive enzymes back into the intestines of the recipient. And then, perhaps as important or maybe more important, you sew the portal vein of the pancreas to the portal venous circulation of the recip-Vol. 233 • No. 5
Pancreatic Transplantation and Graft Biopsy Via Jejunostomy ient. This way, the insulin goes into the liver the way it was designed to. So that's the basic difference.
Now what Gazi has talked about is what I'm going to call the newest way: that is, it modifies that new way by providing a cutaneous outlet to the intestines, which gives the transplant surgeon the added benefit of being able to sample the duodenal secretions and even look at the duodenum for changes in the mucosa and in the biopsy of the mucosa. This is really a neat idea. If you missed it, his 1-year graft survival rate was 92%, and that's pretty good for a pancreas transplantation; that's real good. In fact, of the two grafts he lost, neither one of them were lost to acute rejection. So that is certainly indirect evidence to support that this is a better way to do pancreas transplantation.
I have five questions for you, Gazi. You had four episodes of postop bleeding. You mentioned one of these was GI bleeding. Was this GI bleeding from the duodenal mucosa and was it related to rejection? When you did this endoscopic inspection of the recipient's duodenum through your jejunostomy, was there a clear visual correlation between the rejection you saw on biopsy and what you could see with your eye every time, or was there not complete correlation? In other words, was gross inspection 100% sensitive and 100% specific? Do you need to even do the biopsy? Third, Andy talked about wound rejection. You mentioned that you had five patients with wound rejection. That is fairly high for this, for, as we all know, pancreas transplantations have a high rate of wound complications. In those wound infection patients, you didn't comment on how many were fungal, and you mentioned you used Diflucan as an antifungal prophylaxis. Have you tried using low-dose amphotericin? Of the five patients with wound infection, one had an anastomotic leak. Was this the anastomosis of the neoduodenum to the Roux limb? Was it associated with rejection or not associated? Fifth question: you had two patients with a perforated duodenum. Was this related to endoscopy in any way? Many of us who do bowel surgery have a fresh bowel anastomosis and may be somewhat leery to do endoscopy in the first few days or the first week or two. As you know, rejection is often in the first week or maybe second week, so maybe it is safe to do it then. But did the actual procedure of the endoscopy itself have any deleterious effects?
And In responding to Dr. Klein's questions, I must preface my statements by saying that the four patients included in this oral presentation that had traditional bladder-systemic drainage had a higher incidence of infectious complications than did their entericdrainage cohorts. These patients, perhaps, should not have been included in this analysis and will not be included in the manuscript. Two of the four bladder-systemic patients had wound infections compared to 3 out of 21 patients in the ED group. None of the transplanted organs were lost to infections.
In response to Dr. Klein's question regarding infections that may trigger rejection, I do not feel that the VJ places patients at an increased risk of infection. The higher incidence of rejection seen in our study may be secondary to the ease by which a biopsy can be obtained via the VJ.
In response to Dr. Klein's final question, we have not evaluated the differences in posttransplant blood pressure control between enteric or bladder-drained patients.
Dr. Cofer asked whether GI bleeding seen in our patients was related to rejection. We had four cases of postoperative bleeding but no cases of donor blood vessel weight dextran. While this certainly increases the chances of postoperative bleeding, we would rather deal with postoperative bleeding than portal vein thrombosis. None of these bleeding episodes were the result of rejection; they were the result of anticoagulation. One patient presented 8 months posttransplant with blood per ostomy and underwent endoscopy. She was noted to have a friable donor duodenal mucosa but no rejection. Her bleeding resolved without surgical intervention, and she has not had any rejection or infectious episodes to date.
We are not able to grossly tell the difference between rejection or infection (e.g., cytomegalovirus) during endoscopy, although the mucosa appears hyperemic and friable. Histology remains a very important aspect of diagnosis. With this technique, we were able to obtain a significant amount of material for analysis in every patient biopsied.
None of the patients with wound infections had fungal isolates on cultures of their wounds. We used Diflucan for prophylaxis preoperatively and all patients received Diflucan for 3 months postoperatively. We flushed the donor duodenum with amphotericin at the time of organ recovery, and we liberally irrigated the recipient's abdomen at the time of transplantation, but we did not use systemic amphotericin for fungal prophylaxis in the recipient.
As Dr. Cofer mentioned, one patient had a duodenal stump leak. This patient had undergone a cholecystectomy a few weeks prior for acalculous cholecystitis. This was diagnosed radiographically by placing contrast down the venting jejunostomy.
Two patients had perforations of the donor duodenum. These were not related to endoscopic procedures. In one of these patients, the ostomy had been taken down 8 months prior.
Finally, I believe that Drs. Shokouh-Amiri and Gaber's technique of portal enteric drainage is the best technique for pancreas transplantation. I also believe that patients benefit from having a venting jejunostomy because anastomotic leaks are minimized and easy to detect, biopsies are easily obtained to rule out rejection, and anastomotic GI bleeding can be easily diagnosed and treated. I would like to thank the Society for the privilege of the floor.
